Skip to main content

Kodiak Sciences Inc.

For the period ended Sep 30, 2025. Filed Nov 13, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 13, 2025

KOD$108.06+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

Condensed Consolidated Statements of Cash Flows (unaudited)

(in thousands)

Nine Months Ended September 30,
20252024
Cash flows from operating activities
Net loss$(173,231)$(132,102)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation13,78414,084
Stock-based compensation45,57851,594
Loss on disposal of long-lived assets8—
Non-cash lease impairment expense1,910—
Settlement of derivative contracts—355
Amortization of operating lease right-of-use asset6,0215,940
Changes in assets and liabilities:
Prepaid expenses and other current assets172(827)
Other assets53(24)
Accounts payable6,444(10,330)
Accrued and other current liabilities9,275(7,779)
Operating lease liability(8,144)(8,160)
Long-term deposit1,500—
Net cash used in operating activities(96,630)(87,249)
Cash flows from investing activities
Purchase of property and equipment(463)(251)
Deposits on property and equipment—(25)
Settlement of derivative contracts—(355)
Net cash used in investing activities(463)(631)
Cash flows from financing activities
Proceeds from stock option exercises97538
Proceeds from issuance of common stock pursuant to ESPP8259
Net cash provided by financing activities1,05797
Net (decrease) in cash, cash equivalents and restricted cash(96,036)(87,783)
Cash, cash equivalents and restricted cash, at beginning of period174,258291,831
Cash, cash equivalents and restricted cash, at end of period$78,222$204,048
Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets
Cash and cash equivalents$72,038$197,864
Restricted cash6,1846,184
Total cash, cash equivalents and restricted cash in consolidated balance sheets$78,222$204,048
Supplemental disclosures of non-cash investing and financing information:
Operating lease right-of-use asset obtained in exchange for operating lease liability$—$(49)
Purchase of property and equipment under accounts payable and accruals1214
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.